drugset

drugset / Trial / NCT00381173

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

NCT00381173 ↗

Phase 1 Completed 22 enrolled Eisai Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the feasibility, safety, and tolerability of administering ZYC300 with Cyclophosphamide (Cytoxan).

Timeline

Start: 2006-11
Primary completion: 2008-10
Completion: 2008-10

Publications

Background Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15;11(12):4430-6. doi: 10.1158/1078-0432.CCR-04-2111.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ZYC300	Unknown	400 ug	—
Background	Cyclophosphamide	Other / unclassified	600 mg/m2	Intravenous

Indications